Skip to main content
. 2021 Mar 24;118(13):e2009620118. doi: 10.1073/pnas.2009620118

Fig. 6.

Fig. 6.

MCT4 is related to a methylated phenotype and lowly expressed in MYCN-amplified neuroblastoma. The fold change of MCT4 gene expression from control in the MYCN-amplified (A) SIMA and (B) IMR5 cells treated with 1 µM decitabine for 72 h and RNA processed for qRT-PCR. (C) The fold change of MCT4 gene expression from the GFP-expressing RPE.1 cells and the MYCN-expressing RPE.1 cells. (D) Western blot of the GFP-expressing RPE.1 cells and the MYCN-expressing RPE.1 cells probed with the indicated antibodies. (E) The percentage of expression of 5-methylcytosine in the GFP-expressing RPE.1 cells compared to the MYCN-expressing RPE.1 cells. Transduction with pLenti control or pLenti MCT4 lentivirus in the MYCN-amplified cell lines KELLY and SK-N-BE (2) was performed and cells were assayed for (F) ATP/viability (CellTiter-Glo) following 16 h of treatment with AZD3965 (1, 3, or 10 µM), phenformin (10, 30, or 100 µM), or the combination at the indicated concentrations. (G) The fold-change of gene expression of MCT4 as determined by qRT-PCR and (H) a crystal violet assay following 5 to 7 d of treatment with the combination of 1 µM AZD3965 and 10 µM phenformin.